News headlines about Titan Pharmaceuticals (NASDAQ:TTNP) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Titan Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 46.2410056447632 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Titan Pharmaceuticals (NASDAQ TTNP) remained flat at $$1.33 during mid-day trading on Friday. 208,277 shares of the stock were exchanged, compared to its average volume of 142,578. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 1.67. The firm has a market cap of $28.09, a PE ratio of -1.95 and a beta of 2.07. Titan Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $4.80.
Titan Pharmaceuticals (NASDAQ:TTNP) last posted its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.04). The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.17 million. Titan Pharmaceuticals had a negative net margin of 6,757.29% and a negative return on equity of 146.81%. sell-side analysts predict that Titan Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.
A number of equities research analysts have recently commented on the company. Roth Capital reiterated a “buy” rating and set a $6.00 target price on shares of Titan Pharmaceuticals in a research note on Thursday, October 5th. ValuEngine lowered Titan Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
ILLEGAL ACTIVITY NOTICE: “Titan Pharmaceuticals (TTNP) Receiving Somewhat Positive Media Coverage, Study Finds” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/30/titan-pharmaceuticals-ttnp-receiving-somewhat-positive-media-coverage-study-finds.html.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.